Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44138   clinical trials with a EudraCT protocol, of which   7324   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-005881-17
    Sponsor's Protocol Code Number:RIN-PF-303
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2022-09-19
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2021-005881-17
    A.3Full title of the trial
    A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (TETON-2)
    Studio randomizzato, in doppio cieco, controllato con placebo, multinazionale, di fase 3 sull'efficacia e la sicurezza di treprostinil per via inalatoria in soggetti affetti da fibrosi polmonare idiopatica (TETON-2)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study evaluating the efficacy and safety of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis
    Uno studio che valuta l'efficacia e la sicurezza del treprostinil per via inalatoria nei soggetti con fibrosi polmonare idiopatica
    A.3.2Name or abbreviated title of the trial where available
    -
    -
    A.4.1Sponsor's protocol code numberRIN-PF-303
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT05255991
    A.5.4Other Identifiers
    Name:INDNumber:149587
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorUNITED THERAPEUTICS CORPORATION
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportUNITED THERAPEUTICS CORPORATION
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationUnited Therapeutics Corporation
    B.5.2Functional name of contact pointRegulatory Department
    B.5.3 Address:
    B.5.3.1Street Address55 T.W. Alexander Drive, PO Box 14186
    B.5.3.2Town/ cityResearch Triangle Park, NC
    B.5.3.3Post code27709
    B.5.3.4CountryUnited States
    B.5.4Telephone number0019194858350
    B.5.5Fax number0019198829174
    B.5.6E-mailrtpregulatory@unither.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/22/2588
    D.3 Description of the IMP
    D.3.1Product nameTreprostinil
    D.3.2Product code [-]
    D.3.4Pharmaceutical form Nebulisation solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPInhalation use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTreprostinil
    D.3.9.1CAS number 81846-19-7
    D.3.9.2Current sponsor code-
    D.3.9.4EV Substance CodeSUB21168
    D.3.10 Strength
    D.3.10.1Concentration unit mg/l milligram(s)/litre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number600
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Yes
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboInhalation solution
    D.8.4Route of administration of the placeboInhalation use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Idiopathic Pulmonary Fibrosis
    Fibrosi polmonare idiopatica
    E.1.1.1Medical condition in easily understood language
    Idiopathic Pulmonary Fibrosis
    Fibrosi polmonare idiopatica
    E.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10021240
    E.1.2Term Idiopathic pulmonary fibrosis
    E.1.2System Organ Class 10038738 - Respiratory, thoracic and mediastinal disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the study is to evaluate the safety and efficacy of inhaled treprostinil in subjects with IPF.
    L’obiettivo primario dello studio è valutare la sicurezza e l’efficacia di treprostinil per via inalatoria in soggetti affetti da FPI.
    E.2.2Secondary objectives of the trial
    Not Applicable
    Non applicabile
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Subject gives voluntary informed consent to participate in the study.
    2. Subject is >=40 years of age, inclusive, at the time of signing informed consent.
    3. The subject has a diagnosis of IPF based on the 2018 ATS/ERS/JRS/ALAT Clinical Practice Guideline (Raghu 2018) and confirmed by central review of HRCT (performed within the previous 12 months) and if available, surgical lung biopsy. HRCT imaging must be “consistent with UIP,” defined as meeting either criteria A, B, and C; or criteria A and C; or criteria B and C below:
    a. Subpleural and basal predominant honeycombing
    b. Subpleural and basal predominant reticular pattern with peripheral traction bronchiectasis or traction bronchiolectasis
    c. Absence of atypical features (eg, predominant ground-glass opacity, nodules, consolidation, etc). If ground-glass opacity is present, it must be less than the accompanying reticular pattern.
    Subjects with HRCT features deemed indeterminate for IPF (subpleural and basal predominant, subtle, reticulating pattern of fibrosis) may be considered for inclusion if coupled with a histopathological pattern of “UIP” or “probable UIP” on surgical lung biopsy and confirmed by central review.
    4. FVC >=45% predicted at Screening.
    5. Subjects on pirfenidone or nintedanib must be on a stable and optimized dose for >=30 days prior to Baseline. Concomitant use of both pirfenidone and nintedanib is not permitted.
    6. Women of childbearing potential must be non-pregnant (as confirmed by a urine pregnancy test at Screening and Baseline) and non-lactating, and will do 1 of the following:
    a. Abstain from intercourse (when it is in line with their preferred and usual lifestyle)
    b. Use 2 medically acceptable, highly effective forms of contraception for the duration of the study, and at least 30 days after discontinuing study drug.
    i. Medically acceptable, highly effective forms of contraception can include approved hormonal contraceptives (oral, injectable, and implantable) and barrier methods (such as a condom or diaphragm) when used with a spermicide.
    Women who are successfully sterilized (including hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or postmenopausal (defined as amenorrhea for at least 12 consecutive months) are not considered to be of reproductive potential.
    7. Males with a partner of childbearing potential must use a condom for the duration of treatment and for at least 48 hours after discontinuing study drug.
    8. In the opinion of the Investigator, the subject is able to communicate effectively with study personnel, and is considered reliable, willing, and likely to be cooperative with protocol requirements, including attending all study visits.
    1. Il soggetto fornisce il consenso informato volontario a partecipare allo studio.
    2. Il soggetto ha un'età >=40 anni, inclusi, al momento della firma del modulo di consenso informato.
    3. Il soggetto ha una diagnosi di FPI sulla base delle linee guida ATS/ERS/JRS/ALAT 2018 della pratica clinica (Raghu 2018) e confermata dalla revisione centralizzata dell’HRCT (eseguita nei 12 mesi precedenti) e, se disponibile, dalla biopsia polmonare chirurgica. La diagnostica per immagini HRCT deve essere “coerente con la polmonite interstiziale abituale (Usual Interstitial Pneumonia, [UIP])”, definita come soddisfacimento dei criteri A, B e C; o dei criteri A e C; o dei criteri B e C descritti di seguito:
    a. Alveolatura subpleurica e basale predominante
    b. Schema reticolare predominante subpleurico e basale con bronchiettasia da trazione periferica o bronchioettasia da trazione
    c. Assenza di caratteristiche atipiche (per es., opacità predominante a vetro smerigliato, noduli, consolidamento, ecc.). Se è presente opacità a vetro smerigliato, deve essere inferiore al modello reticolare corrispondente.
    I soggetti con caratteristiche rilevate dall’HRCT ritenute indeterminate per l’IPF (modello sottile e reticolare di fibrosi a predominanza subpleurica e basale) possono essere presi in considerazione per l'inclusione se accoppiati a un modello istopatologico di "UIP" o "probabile UIP" alla biopsia polmonare chirurgica e confermato dalla revisione centralizzata.
    4. CVF >=45% prevista allo screening.
    5. I soggetti che assumono pirfenidone o nintedanib devono assumere una dose stabile e ottimizzata per >=30 giorni prima del basale. Non è consentito l’uso concomitante di pirfenidone e nintedanib.
    6. Le donne in età fertile non devono essere in gravidanza (secondo quanto confermato da un test di gravidanza sulle urine allo screening e al basale) e non devono allattare al seno e effettueranno 1 di quanto segue:
    a. Astenersi dai rapporti sessuali (quando in linea con il loro stile di vita preferito e abituale)
    b. Utilizzare 2 metodi contraccettivi altamente efficaci e accettabili dal punto di vista medico per tutta la durata dello studio e almeno 30 giorni dopo l’interruzione del farmaco in studio.
    i. I metodi contraccettivi altamente efficaci e accettabili dal punto di vista medico possono includere contraccettivi ormonali approvati (orali, iniettabili e impiantabili) e metodi barriera (come un preservativo o diaframma) quando utilizzati con uno spermicida.
    Le donne sterilizzate con successo (comprese isterectomia, salpingectomia bilaterale oppure ooforectomia bilaterale) o in post-menopausa (definita come amenorrea da almeno 12 mesi consecutivi) non sono considerate potenzialmente fertili.
    7. I soggetti di sesso maschile con una partner in età fertile devono utilizzare un preservativo per tutta la durata del trattamento e per almeno 48 ore dopo l’interruzione del farmaco in studio.
    8. A giudizio dello sperimentatore, il soggetto è in grado di comunicare efficacemente con il personale dello studio ed è considerato affidabile, disposto e probabilmente cooperativo per quanto concerne i requisiti del protocollo, inclusa la partecipazione a tutte le visite dello studio.
    E.4Principal exclusion criteria
    1. Subject is pregnant or lactating
    2. Subject has primary obstructive airway physiology: FEV1/FVC <0.70 at Screening.
    3. The subject has shown intolerance or significant lack of efficacy to a prostacyclin or prostacyclin analogue that resulted in discontinuation or inability to effectively titrate that therapy.
    4. The subject has received any PAH-approved therapy, including prostacyclin therapy (epoprostenol, treprostinil, iloprost, or beraprost; except for acute vasoreactivity testing), IP receptor agonists (selexipag), endothelin receptor antagonists, phosphodiesterase type 5 inhibitors (PDE5-Is), or soluble guanylate cyclase stimulators within 60 days prior to Baseline. As needed use of a PDE5-I for erectile dysfunction is permitted, provided no doses are taken within 48 hours of any study-related efficacy assessments.
    5. Use of any of the following medications:
    a. Azathioprine (AZA), cyclosporine, mycophenolate mofetil, tacrolimus, oral corticosteroids (OCS) >20 mg/day or the combination of OCS+AZA+N-acetylcysteine within 30 days prior to Baseline.
    b. Cyclophosphamide within 60 days prior to Baseline
    c. Rituximab within 6 months prior to Baseline
    6. The subject is receiving >10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
    7. Exacerbation of IPF or active pulmonary or upper respiratory infection within 30 days prior to Baseline. Subjects must have completed any antibiotic or steroid regimens for treatment of the infection or acute exacerbation more than 30 days prior to Baseline to be eligible. If hospitalized for an acute exacerbation of IPF or a pulmonary or upper respiratory infection, subjects must have been discharged more than 90 days prior to Baseline to be eligible.
    8. Uncontrolled cardiac disease, defined as myocardial infarction within 6 months prior to Baseline or unstable angina within 30 days prior to Baseline.
    9. In the opinion of the Investigator, the subject has any condition that would interfere with the interpretation of study assessments or would impair study participation or cooperation.
    10. Use of any other investigational drug/device or participation in any investigational study in which the subject received a medical intervention (ie, procedure, device, medication/supplement) within 30 days prior to Screening. Subjects participating in non-interventional, observational, or registry studies are eligible.
    11. Life expectancy <6 months due to IPF or a concomitant illness.
    12. Acute pulmonary embolism within 90 days prior to Baseline
    1. Il soggetto è in stato di gravidanza o in allattamento.
    2. Il soggetto presenta una fisiologia primaria ostruttiva delle vie aeree: FEV1/FVC <0,70 allo screening.
    3. Il soggetto ha mostrato intolleranza o mancanza significativa di efficacia a una prostaciclina o a un analogo della prostaciclina, che ha determinato l’interruzione o l’impossibilità di titolare tale terapia in modo efficace.
    4. Il soggetto ha ricevuto qualsiasi terapia approvata per l’ipertensione arteriosa polmonare (IAP), inclusa la terapia con prostaciclina (epoprostenolo, treprostinil, iloprost o beraprost; fatta eccezione per il test della vasoreattività acuta), gli agonisti del recettore IP (selexipag), gli antagonisti del recettore dell’endotelina, gli inibitori della fosfodiesterasi di tipo 5 (PDE5 Is) o gli stimolatori solubili della guanilato ciclasi nei 60 giorni prima del basale. Se necessario, è consentito l’uso di un PDE5 I per la disfunzione erettile, a condizione che non siano assunte dosi entro 48 ore da eventuali valutazioni di efficacia correlate allo studio.
    5. Uso di uno qualsiasi dei seguenti farmaci:
    a. Azatioprina (AZA), ciclosporina, micofenolato mofetile, tacrolimus, corticosteroidi orali (CSO) >20 mg/die o la combinazione di CSO+AZA+N acetilcisteina nei 30 giorni prima del basale.
    b. Ciclofosfamide nei 60 giorni prima del basale
    c. Rituximab nei 6 mesi prima del basale
    6. Il soggetto sta ricevendo un supplemento di ossigeno >10 l/min mediante qualsiasi modalità di somministrazione a riposo al basale.
    7. Riacutizzazione della FPI o dell’infezione polmonare o delle vie respiratorie superiori attiva nei 30 giorni prima del basale. Per essere idonei, i soggetti devono aver completato un qualsiasi regime antibiotico o steroideo per il trattamento dell’infezione o della riacutizzazione da oltre 30 giorni prima del basale. Se ricoverati, per essere idonei, i soggetti devono essere stati dimessi a seguito di una riacutizzazione dell’FPI o di un’infezione polmonare o delle vie respiratorie superiori da oltre 90 giorni prima del basale.
    8. Cardiopatia non controllata, definita come infarto miocardico nei 6 mesi prima del basale o angina instabile nei 30 giorni prima del basale.
    9. A giudizio dello sperimentatore, il soggetto presenta una qualsiasi condizione che potrebbe interferire con l’interpretazione delle valutazioni dello studio o compromettere la partecipazione o la cooperazione allo studio.
    10. Uso di qualsiasi altro farmaco/dispositivo sperimentale o partecipazione a qualsiasi studio sperimentale in cui il soggetto abbia ricevuto un intervento medico (ovvero, procedura, dispositivo, farmaco/integratore) nei 30 giorni precedenti lo screening. I soggetti che partecipano a studi non interventistici, osservazionali o di registro sono idonei.
    11. Aspettativa di vita <6 mesi a causa della FPI o di una malattia concomitante.
    12. Embolia polmonare acuta nei 90 giorni prima del basale.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint of the study is the change in absolute forced vital capacity (FVC) in subjects with IPF from baseline to Week 52.
    L'endpoint primario di efficacia dello studio è la variazione della capacità vitale forzata (CVF) assoluta nei soggetti con FPI dal basale alla Settimana 52.
    E.5.1.1Timepoint(s) of evaluation of this end point
    From baseline to Week 52.
    Dal basale alla Settimana 52.
    E.5.2Secondary end point(s)
    Secondary efficacy endpoints of the study are:
    • Time to clinical worsening (including time to death, respiratory hospitalization, or >=10% relative decline in % predicted FVC)
    • Time to first acute exacerbation of IPF
    • Overall survival at Week 52
    • Change from baseline in % predicted FVC at Week 52
    • Change from baseline in King’s Brief Interstitial Lung Disease Questionnaire (K-BILD) score at Week 52
    Gli endpoint di efficacia secondari dello studio sono:
    • Tempo al peggioramento clinico (compresi il tempo al decesso, al ricovero per motivi respiratori o al declino relativo >=10% della CVF prevista in %)
    • Tempo alla prima riacutizzazione della FPI
    • Sopravvivenza globale alla Settimana 52
    • Variazione nella percentuale di CVF prevista dal basale alla Settimana 52
    • Variazione rispetto al basale nel punteggio del questionario breve sulla pneumopatia interstiziale del King's College (King's Brief Interstitial Lung Disease Questionnaire, [K-BILD]) alla Settimana 52
    E.5.2.1Timepoint(s) of evaluation of this end point
    From baseline to Week 52.
    Dal basale alla Settimana 52.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned8
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA55
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Australia
    Chile
    Israel
    Korea, Republic of
    Mexico
    New Zealand
    Peru
    Taiwan
    France
    Netherlands
    Spain
    Germany
    Italy
    Belgium
    Denmark
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last Patient Last Visit
    Ultima visita dell'ultimo paziente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months9
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months8
    E.8.9.2In all countries concerned by the trial days19
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 20
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 376
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state31
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 200
    F.4.2.2In the whole clinical trial 396
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Subjects who complete the Week 52 Visit may be offered the opportunity to enter an OLE study after completing the final study visit.
    Ai soggetti che completano la visita della Settimana 52 potrebbe essere offerta l’opportunità di accedere a uno studio di estensione in aperto (open-label extension, [OLE]) dopo aver completato la visita finale dello studio.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-10-25
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-11-21
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA